Project Grant HT9425261E163
Award Date 9/30/26
Completion Date 9/29/30
Dollars Obligated $2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.12M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026, through August 31, 2030. The award supports resource development activities aimed at improving clinical and research outcomes for blastic plasmacytoid dendritic cell neoplasm, a rare hematologic malignancy. The project deliverables will advance knowledge and...
- The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research aimed at understanding and therapeutically targeting treatment-emergent neuroendocrine prostate cancer. As a leading academic medical research institution, DFCI will leverage its expertise in oncology, immunology, molecular...
- The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
- The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
- Award Summary Dana-Farber Cancer Institute, Inc. received a $560.0K Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to develop novel digenic combination therapies for treatment of pancreatic cancer. The award period runs from September 1, 2026, through August 31, 2028, and supports hypothesis-driven biomedical research addressing Service Member health and military-relevant medical conditions. As a leading academic...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $4.2 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2030. The award funds research and development of optimized B7-H3 Chimeric Antigen Receptor (CAR) T cell therapies targeting children and young adults with sarcomas and other B7-H3-positive solid tumors. This initiative represents a...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1,014,596 Project Grant award dated July 15, 2026, from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support research on optimizing immunotherapy for pediatric solid tumors. The three-year award, with an ultimate completion date of July 14, 2029, funds research initiatives at the institute's Boston, Massachusetts location aimed at advancing...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $752,238 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026, through June 30, 2029. This three-year award supports the development of explainable artificial intelligence (AI) systems designed to predict melanoma progression and survival outcomes. The project addresses a significant clinical need within the military...